According to the MHRA product information, the most frequently reported adverse reactions include: Nausea and vomiting : Very common (affecting more than 1 in 10 people), typically most pronounced during the first 48 weeks of treatment or following dose escalation Diarrhoea : Common (affecting up to 1 in 10 people), with frequency increasing at higher doses Abdominal pain or discomfort : Often described as cramping or bloating sensations Decreased appetite : A direct result of the medication's action on satiety centres Constipation : Less common than diarrhoea but can occur in some individuals Dyspepsia (indigestion) : Characterised by upper abdominal discomfort or burning The timing of these side effects follows a predictable pattern in most patients
Complementary mechanisms, generally well-tolerated
Reduced appetite is the intended effect, though sometimes it feels extreme
The FDA, EMA, and PMDA have all evaluated Semaglutide raw powder formulations and established safety guidelines that your healthcare provider should review with you before beginning treatment
Are Wegovy, Ozempic, and generic semaglutide all the same
However, the tirzepatide ODT cannot be shipped to California, Wisconsin, Iowa, or Minnesota due to state-specific compounding regulations